Clinical effect of trimetazidine on hypertensive heart disease
曲美他嗪治疗高血压性心脏病的临床效果

摘要

目的 分析高血压性心脏病中曲美他嗪治疗的干预效果。方法 选择近2年（2020年1月-2022年2月）本院收治的高血压性心脏病患者80例，回顾临床资料，将加用曲美他嗪治疗的40例作为观察组，采用常规治疗的45例患者作为对照组，对比两组临床疗效。结果 治疗后，观察组患者血压（舒张压、收缩压）、心率及血浆脑利钠肽水平改善情况更佳，临床疗效更高，与对照组相比差异有统计学意义（P<0.05）；随访1年内，观察组患者再住院率及心血管死亡率更低，与对照组相比差异有统计学意义（P<0.05）。结论 既往常规治疗方案在治疗高血压性心脏病中效果良好，但加入曲美他嗪能进一步改善患者临床症状和预后，且减少再住院率和心血管死亡率，临床应用价值确切。

Abstract

Objective To analyze the intervention effect of trimetazidine on hypertensive heart disease.
Methods: 80 patients with hypertensive heart disease admitted to our hospital in recent 2 years (January 2020 February 2022) were selected. The clinical data were reviewed. 40 patients who were treated with trimetazidine were treated as the observation group, and 45 patients who were treated with conventional therapy were treated as the control group. The clinical effects of the two groups were compared.
Results: After treatment, the blood pressure (diastolic blood pressure, systolic blood pressure), heart rate and plasma brain natriuretic peptide level of the patients in the observation group improved better, and the clinical effect was higher than that of the control group, with a statistically significant difference (P<0.05); During the 1-year follow-up, the readmission rate and cardiovascular mortality rate of patients in the observation group were lower than those in the control group (P<0.05).
Conclusion  : The previous conventional treatment scheme has a good effect in the treatment of hypertensive heart disease, but the addition of trimetazidine can further improve the clinical symptoms and prognosis of patients, and reduce the readmission rate and cardiovascular mortality. The clinical application value is definite.